ARS Pharmaceuticals Inc
NASDAQ:SPRY

Watchlist Manager
ARS Pharmaceuticals Inc Logo
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Watchlist
Price: 11.38 USD -0.87% Market Closed
Market Cap: 1.1B USD

Wall Street
Price Targets

SPRY Price Targets Summary
ARS Pharmaceuticals Inc

Wall Street analysts forecast SPRY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SPRY is 28.39 USD with a low forecast of 12.12 USD and a high forecast of 36.75 USD.

Lowest
Price Target
12.12 USD
7% Upside
Average
Price Target
28.39 USD
149% Upside
Highest
Price Target
36.75 USD
223% Upside
ARS Pharmaceuticals Inc Competitors:
Price Targets
SLS
Sellas Life Sciences Group Inc
143% Upside
FHTX
Foghorn Therapeutics Inc.
110% Upside
ALXO
ALX Oncology Holdings Inc
130% Upside
ACE
Ascelia Pharma AB
157% Upside
006280
Green Cross Corp
26% Upside
PBYI
Puma Biotechnology Inc
23% Downside
ARWR
Arrowhead Pharmaceuticals Inc
10% Downside
AVCT
Avacta Group PLC
56% Upside

Revenue
Forecast

Revenue Estimate
ARS Pharmaceuticals Inc

The compound annual growth rate of ARS Pharmaceuticals Inc's revenue for the next 4 years is 53%.

N/A
Past Growth
53%
Estimated Growth
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
ARS Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-11%
Average Miss

Net Income
Forecast

Net Income Estimate
ARS Pharmaceuticals Inc

The compound annual growth rate of ARS Pharmaceuticals Inc's net income for the next 4 years is 49%.

N/A
Past Growth
49%
Estimated Growth
Estimates Accuracy
-70%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SPRY's stock price target?
Price Target
28.39 USD

According to Wall Street analysts, the average 1-year price target for SPRY is 28.39 USD with a low forecast of 12.12 USD and a high forecast of 36.75 USD.

What is ARS Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
53%

The compound annual growth rate of ARS Pharmaceuticals Inc's revenue for the next 4 years is 53%.

What is ARS Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
49%

The compound annual growth rate of ARS Pharmaceuticals Inc's net income for the next 4 years is 49%.

Back to Top